Refers to a compound of formula I: where R1, R2 and R3 are independently h, F, CL, - NH2, among others R4 is H, F, CL, CN, ciclopropilo, among others R5 is - CH3 and - CH2CH3, - CH2OH, R6 h, among others F, - CH3, among others R7 is selected, among others R8 is - S (o) - CH3, 2C H3, ciclopropilo, among others x1 R9 CR9 or n where f is H, CH3, among others x2 is CR10 or n,Where R10 is H, CH3, CH2CH3, among others y1 and Y2 are independently ch and N.Preferred compounds are: (S) - 2 - (5 - fluoro - 2 - (hydroxymethyl) - 3 - (1 - methyl - 5 - (5 - (2 - methyl - 4 - (3 - oxetan - il) piperazin-1-yl) pyridin - 2 - oxo - ilamino) - 6 dihidropiridin - 1.6 - il) phenyl) - 3 - 3,4,6,7,8,9 - hexahidropirido [3,4-b] indolizin - 1 (2H) - One (S) - 5 - [5-fluoro-2 - (hydroxymethyl) - 3 - 1 - methyl - 5 - (5 - (2 - methyl - 4 - (oxetan - 3 - il) P Iperazin) pyridin - il - 1 - 2 - ilamino) - 6 - oxo - 1.6 - dihidropiridin) phenyl] - 3 - il - 8 - tia - 4.5 - diazatriciclo [7.4.0.02,7 trideca (9)] - 1, 2, 3 - (7) - 6 - One triennium 2008-2010. This Compound is an inhibitor of Btk (Brutons tyrosine kinase). It also relates to a Pharmaceutical composition, and Methods for obtaining being useful in the treatment of immune disorders.SE REFIERE A UN COMPUESTO DE FORMULA I DONDE: R1, R2 Y R3 SE SELECCIONAN INDEPENDIENTEMENTE DE H, F, CL, -NH2, ENTRE OTROS R4 ES H, F, CL, CN, CICLOPROPILO, ENTRE OTROS R5 ES -CH3, -CH2CH3, -CH2OH, ENTRE OTROS R6 ES H, F, -CH3, ENTRE OTROS R7 SE SELECCIONA DE A, ENTRE OTROS R8 ES -CH3, -S(O)2CH3, CICLOPROPILO, ENTRE OTROS X1 ES CR9 O N DONDE R9 ES H, F, CH3, ENTRE OTROS X2 ES CR10 O N, DONDE R10 ES H, CH3, CH2CH3, ENTRE OTROSY1 Y Y2 SON INDEPENDIENTEMENTE ENTRE SI CH Y N. SON COMPUESTOS PREFERIDOS: (S)-2-(5-FLUORO-2-(HIDROXIMETIL)-3-(1-METIL-5-(5-(2-METIL-4-(OXETAN-3-IL)PIPERAZIN-1-IL)PIRIDIN-2-ILAMINO)-6-OXO-1,6-DIHIDROPIRIDIN-3-IL)FENIL)-3,4,6,7,8,9-HEXAHIDROPIRIDO[3,4-B]INDOLIZIN-1(2H)-ONA (S)-5-[5-FLUORO-2-HIDROXIMETIL)-3-(1-METIL-5-(5-(2-METIL-4-(OXETAN
